Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan

International Journal of Rheumatic Diseases

Volumn 17, Issue s3, 2014, Pages 9-19

  Chiu, Ying Ming ^a,b   Lang, Hui Chu ^c   Lin, Hsiao Yi ^d   Yang, Ming Ta ^e   Fang, Chi Hui ^f,g   Yang, Ya Wen ^f,g   Schabert, Vernon F ^e   Tang, Boxiong ^f,g  

^a CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^b HUNGKUANG UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e IQVIA   (United States)

^f PFIZER   (Taiwan)

^g PFIZER INC   (United States)

Author keywords

Epidemiology; Health services and health care economics; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; AUROTHIOMALATE; AZATHIOPRINE; BETAMETHASONE; CORTISONE; CYCLOSPORIN; DEXAMETHASONE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FLUOCORTOLONE; HYDROCORTISONE; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MINOCYCLINE; PARAMETHASONE; PENICILLAMINE; PREDNISOLONE; PREDNISONE; PREDNYLIDENE; RITUXIMAB; SALAZOSULFAPYRIDINE; TRIAMCINOLONE; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BACTERIAL INFECTION; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; DRUG EXPOSURE; DRUG SAFETY; DRUG USE; FEMALE; HUMAN; INCIDENCE; LONGITUDINAL STUDY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; STEROID THERAPY; TAIWAN; TUBERCULOSIS; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; FACTUAL DATABASE; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; OPPORTUNISTIC INFECTIONS; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; CHI-SQUARE DISTRIBUTION; DATABASES, FACTUAL; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; LOGISTIC MODELS; LONGITUDINAL STUDIES; LYMPHOMA; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PROPENSITY SCORE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TAIWAN; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84921064089     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.12539     Document Type: Article

References (43)

1. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P (2007) New therapies for treatment of rheumatoid arthritis. Lancet 370, 1861-74.
2. National Institute for Health and Clinical Excellence (2010) Rheumatoid Arthritis. (Clinical Guideline CG79). Available from URL: http://guidance.nice.org.uk/CG79Guidance/.
3. Saag KG, Teng GG, Patkar NM et al. (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59, 762-84.
4. Smolen JS, Landewe R, Breedveld FC et al. (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69, 964-75.
5. Keystone EC, Kavanaugh AF, Sharp JT et al. (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50, 1400-11.
6. Dixon WG, Symmons DP, Lunt M et al. (2007) Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 56, 2896-904.
7. Lipsky PE, van der Heijde DM, St Clair EW et al. (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343, 1594-602.
8. Weinblatt ME, Kremer JM, Bankhurst AD et al. (1999) A Trial of Etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340, 253-9.
9. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE (2002) Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 46, 2287-93.
10. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM (2002) Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 46, 3151-8.
11. Favalli EG, Desiati F, Atzeni F et al. (2009) Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients. Autoimmun Rev 8, 266-73.
12. Smitten AL, Choi HK, Hochberg MC et al. (2008) The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 35, 387-93.
13. Tugwell P, Singh JA, Wells GA (2011) Biologicals for rheumatoid arthritis. BMJ 343, d4027.
14. Keane J, Gershon S, Wise RP et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345, 1098-104.
15. Curtis JR, Patkar N, Xie A et al. (2007) Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 56, 1125-33.
16. Galloway JB, Hyrich KL, Mercer LK et al. (2011) Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 50 (1), 124-31.
17. Listing J, Strangfeld A, Kary S et al. (2005) Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 52, 3403-12.
18. Askling J, Fored CM, Brandt L et al. (2005) Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 52, 1986-92.
19. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, BIOBADASER Group (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48, 2122-7.
20. Seong SS, Choi CB, Woo JH et al. (2007) Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 34, 706-11.
21. Wolfe F, Michaud K, Anderson J, Urbansky K (2004) Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 50, 372-9.
22. Wallis RS (2008) Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 8, 601-11.
23. Salmon-Ceron D, Tubach F, Lortholary O et al. (2011) Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 70, 616-23.
24. Dixon WG, Watson K, Lunt M et al. (2006) Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54, 2368-76.
25. Dixon WG, Hyrich KL, Watson KD et al. (2010) Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69, 522-8.
26. Tubach F, Salmon D, Ravaud P et al. (2009) Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 60, 1884-94.
27. Mariette X, Gottenberg JE, Ravaud P, Combe B (2011) Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology (Oxford) 50 (1), 222-9.
28. Wolfe F, Michaud K (2004) Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18, 572 patients. Arthritis Rheum 50, 1740-51.
29. Ruan SY, Chuang YC, Wang JY et al. (2012) Revisiting tuberculous pleurisy: pleural fluid characteristics and diagnostic yield of mycobacterial culture in an endemic area. Thorax 67, 822-7.
30. Bureau of National Health Insurance, Department of Health, Executive Yuan (2011) National Health Insurance in Taiwan 2011 Annual Report. Available from URL: http://www.nhi.gov.tw/Resource/webdata/13767_1_NHIINTAIWAN2011ANNUALREPORT.pdf. Accessed May 16, 2012
31. Arnett FC, Edworthy SM, Bloch DA et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31, 315-24.
32. Cohen J (1988) Statistical Power Analysis for the Behavioral Sciences. 2nd edn. Lawrence Erlbaum, Hillsdale, NJ.
33. Mercer L, Davies R, Galloway J et al. (2013) Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology 52, 91-8.
34. Hellgren K, Smedby K, Feltelius N, Baecklund E, Askling J (2010) Do rheumatoid arthritis and lymphoma share risk factors? Arthritis Rheum 62, 1252-8.
35. Ekstrom K, Hjalgrim H, Brandt L et al. (2003) Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first degree relatives. Arthritis Rheum 48, 963-70.
36. Baecklund E, Akbom A, Sparen P, Fektekius N, Klareskog L (1998) Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 317, 180-1.
37. Symmons D (2007) Lymphoma and rheumatoid arthritis - again. Rheumatology 46, 1-2.
38. Mattey D, Thomson W, Ollier W et al. (2007) Association of DRB1 shared epitope genotypes with early mortality in rheumatoid arthritis: results of eighteen years of follow-up from the early rheumatoid arthritis study. Arthritis Rheum 56, 1408-16.
39. United Kingdom Health Protection Agency. Geography - TB data by country. Available from URL: http://www.hpa.org.uk.
40. United Kingdom Health Protection Agency (2010) World Health Organization (WHO) estimates of tuberculosis incidence by country, 2010. Available from URL: http://www.hpa.org.uk.
41. National Health Insurance Research Database, Taiwan. Available from URL: http://www.nhri.org.tw/nhird/en/index.htm. Accessed May 18, 2012.
42. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE (2002) Predictors of infection in rheumatoid arthritis. Arthritis Rheumatol 46, 2294-300.
43. U.S. Centers for Disease Control and Prevention (2010) Trends in Tuberculosis, 2010. Available from URL: http://www.cdc.gov/tb/publications/factsheets/statistics/TBTrends.htm. Accessed May 16, 2012.